<DOC>
	<DOCNO>NCT00911261</DOCNO>
	<brief_summary>The purpose study determine Oxymorphone Extended Release effective safe treat chronic pain patient cancer neuropathic pain .</brief_summary>
	<brief_title>Oxymorphone Extended Release Patients With Cancer Neuropathic Pain</brief_title>
	<detailed_description>The purpose study evaluate analgesic effectiveness tolerability oxymorphone ER treatment cancer neuropathic pain . Opioid-naïve subject gradually titrate oxymorphone ER 5 mg , every 12 hour ( q12h ) . All subject titrate stable dose ( defined pain score ≥ 4 BPI Question 5 3 5 consecutive day receive total daily dose study medication include rescue ) tolerable side effect . Subjects could potentially receive therapy 12 month first dose study medication .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Oxymorphone</mesh_term>
	<criteria>≥ 18 year age old , moderate severe chronic malignant and/or neuropathic pain least 3 month duration either : 1. initial pain intensity score great 4 10point scale use BPI Question 5 , suboptimally respond current analgesic regimen , 2. intolerable side effect one component current opioidcontaining analgesic regimen . Currently receive stable ( least 2 week duration ) analgesic regimen If female , must practice abstinence use medically acceptable form contraception ( e.g. , intrauterine device , hormonal birth control , double barrier method ) . Understand write speak English Have inform nature study provide write informed consent Additional Inclusion Criteria Cancer Patients Only : Have life expectancy least 12 month Additional Inclusion Criteria Neuropathic Patients Only : Have diagnosis : postherpetic neuralgia ( PHN ) diabetic neuropathy ( DN ) complex regional pain syndrome ( CRPS ) HIV neuropathy idiopathic sensory neuropathy traumatic peripheral neuropathy central neuropathic pain condition ( spinal cord injury , poststroke pain ) , OR peripheral neuropathy ( upon mutual agreement sponsor investigator ) . Have positive pregnancy test ( female ) Have history active asthma emphysema Have clinically significant hepatic impairment Have history alcohol substance abuse within last 3 year Have history opioid abuse within 6 month prior study entry Have know allergy significant reaction opioids , include codeine Have know oxymorphone sensitivity allergy Have receive investigational drug product participate investigational drug study within period 30 day prior receive study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Cancer Pain</keyword>
	<keyword>Neuropathic Pain</keyword>
	<keyword>Extended Release</keyword>
	<keyword>Long-Acting Opioid</keyword>
	<keyword>Oxymorphone</keyword>
</DOC>